Dr. Paul R. Fortin, MD, MPH, FRCPC holds the Tier 1 Canada Research Chair in Systemic Autoimmune Rheumatic Diseases, is Professor at Laval University, and Clinical Investigator at the CHU Research Center of Quebec – Laval University. He obtained his medical degree from Laval University and is a graduate of McGill University in rheumatology. He then obtained a Master’s in Public Health from Harvard University’s School of Public Health.
Dr. Fortin is working to better understand the bio-psycho-social impact of systemic autoimmune rheumatic diseases (SARD), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, inflammatory myositis, and antiphospholipid syndrome (APS). He is particularly interested in the development of interventions for the treatment of SLE, RA, and APS.
His methodological interests are the development and validation of diagnostic and prognostic tests, new treatments, and new ways to measure the impact of these treatments on the health status of the patient, and on the levels of activity or harm of the disease within SARDs. His other methodological interests include developing healthy lifestyle habits for people with SARD, and measuring the impact of patient knowledge.
Since 2011, Dr. Fortin has been working on the creation and establishment of a new computerized database and biobank that enables the collection of informative biospecimens and clinical data relevant to the study of SARDs. This biobank and database now has more than 13,000 biospecimens, from over 250 people, and has already contributed to translational and clinical research projects, as well as two projects funded by the Canadian Institutes of Health Research.
Dr. Fortin received the Canadian Rheumatology Association (CRA) Young Investigator Award in 1999, the Kirkland Scholar Award in 2008, and the prestigious Research Achievement Award from The Arthritis Society of Canada (2007- 2012). In 2010, he received the Lupus Ontario Hope Award for his outstanding leadership in improving the lives of people with lupus. In May 2015, he received the Jeffrey Shiroky Research Award for his clinical research achievements in rheumatology.
2705, boulevard Laurier
T0-97
Québec, Québec
Canada G1V 4G2
Latest news
- Amiable, NathalieEmployeeCHUL+1 418-525-4444, extension 42784Nathalie.Amiable@crchudequebec.ulaval.ca
2705, boulevard Laurier
T0-83
Québec, Québec
Canada G1V 4G2 - Boisvert, AnaEmployeeCHUL+1 418-525-4444, extension 42296ana.boisvert@crchudequebec.ulaval.ca
2705, boulevard Laurier
T2-50
Québec, QC
Canada G1V 4G2 - Bouhouta, AzizaEmployeeCHUL+1 418-525-4444, extension 48280aziza.bouhouta@crchudequebec.ulaval.ca
2705 Boulevard Laurier
T0-83
Québec, QC
Canada G1V 4G2 - Cazes, AmélyEmployeeCHUL+1 418-525-4444, extension 46076amely.cazes@crchudequebec.ulaval.ca
2705, boulevard Laurier
T0-83
Québec, QC
Canada G1V 4G2 - Crépeau, FrédériqueEmployeeCHUL+1 418-525-4444, extension 42296frederique.crepeau@crchudequebec.ulaval.ca
2705, boulevard Laurier
T1-49
Québec, QC
Canada G1V 4G2 - Godbout, AlexandraEmployeeCHUL+1 418-525-4444, extension 48456+1 418-654-2142Alexandra.GodBout@crchudequebec.ulaval.ca
2705, boulevard Laurier
T0-83
Québec, Québec
Canada G1V 4G2 - Rollet-Labelle, EmmanuelleEmployeeCHUL+1 418-525-4444, extension 47969+1 418-654-2765emmanuelle.rollet@crchudequebec.ulaval.ca
2705, boulevard Laurier
T0-83
Québec, Québec
Canada G1V 4G2
Health Care Utilization in Systemic Sclerosis Patients With Digital Ulcers
Journal ArticleArthritis Care Res (Hoboken), 75 (5), 2023.
Measuring the Impact of MyLupusGuide in Canada: Results of a Randomized Controlled Study
Journal ArticleArthritis Care Res (Hoboken), 75 (3), 2023.
Evaluating the Construct of Damage in Systemic Lupus Erythematosus
Journal ArticleArthritis Care Res (Hoboken), 75 (5), 2023.
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine
Journal ArticleLupus Sci Med, 9 (1), 2022.
Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic
Journal ArticleLupus Sci Med, 9 (1), 2022.
Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry")
Journal ArticleLupus, 31 (14), 2022.
The role of mitochondria in rheumatic diseases
Journal ArticleNat Rev Rheumatol, 18 (11), 2022.
Measuring the impact of an educational intervention in rheumatoid arthritis: An open-label, randomized trial
Journal ArticleArch Rheumatol, 37 (2), 2022.
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
Journal ArticleAnn Rheum Dis, 81 (11), 2022.
A liquid chromatography-mass spectrometry assay for the quantification of nucleotide sugars in human plasma and urine specimens and its clinical application
Journal ArticleJ Chromatogr A, 1677 , 2022.
Active projects
- Canada research chair in Innovate Systemic Autoimmune Rheumatic Disease, from 2019-07-01 to 2026-06-30
- FcgRI as a potential therapeutic target in inflammatory arthritis, from 2022-01-01 to 2025-03-31
- Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-04-01 to 2025-03-31
- Role of megakaryocytes in Systemic Lupus Erythematosus, from 2023-04-01 to 2028-03-31
- Role of phosphatidylserine-specific phospholipase A1 (PLA1A) in the pathogenesis of rheumatic diseases, from 2023-01-01 to 2025-12-31
Recently finished projects
- Booster dose of mRNA SARS-CoV-2 vaccine vs non mRNA vaccine for people living with systemic autoimmune rhumatic diseases without adequate humoral response post standard mRNA vaccination, from 2021-12-01 to 2022-11-30
- CompreHensive Analysis of Mitochondria in Pathogenesis of SLE (CHAMPS), from 2021-09-01 to 2022-08-31
- COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases / La réponse immunitaire au vaccin contre la COVID-19 chez des patients immunosupprimés en raison de maladies auto-immunes, from 2021-03-16 to 2023-03-31
- Hydroxychloroquine in systemic lupus, from 2018-04-01 to 2023-03-31
- Maladies Rhumatismales Autoimmunes Systémiques (MRAS) , from 2020-12-15 to 2023-03-31
- Mapping anti-mitochondrial antibodies in systemic lupus erythematosus, from 2019-04-01 to 2022-03-31
- Megakaryocyte: a new player in systemic lupus erythematosus, from 2022-09-01 to 2023-08-31
- Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-01-01 to 2022-12-31
- Projet de recherche sur les maladies arthritiques, from 2019-12-01 to 2021-11-30
- Role of autotaxin bound to platelet-derived microparticles to development of vascular damage in arthritis., from 2015-07-01 to 2023-03-31
- Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED) , from 2021-04-01 to 2023-09-30
- The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2- the CoVIRAL project, from 2020-04-01 to 2023-03-31
- Understanding the pathogenesis of COVID-19, from 2020-03-01 to 2023-02-28
- Unité support du Québec: Un soutien pour la recherche axée sur le patient, from 2014-04-01 to 2022-03-31